Saving the lives of patients with chronic kidney disease AstraZenelan has reached the clinical end of all phase 3.

CKD is a serious disease that affects nearly 700 million people worldwide.
currently have limited treatment options for these patients.
CKD was associated with a significant increase in cardiovascular event risk, such as heart failure (HF) and premature death.
is a "first-in-class" oral SGLT2 inhibitor.
SGLT2 is a transport protein in the kidneys that assists in glucose re-absorption.
SGLT2 inhibitors reduce glucose levels in the blood by inhibiting the function of SGLT2 by allowing more glucose to be excreted from the urine.
has been approved by the FDA to improve blood sugar control in people with type 2 diabetes, together with diet and exercise, and to lower their weight and blood pressure.
has also been approved by the European Union for the treatment of people with type 1 diabetes.
last August, the FDA granted Dagrid net fast-track status to slow the progression of kidney failure and prevent cardiovascular disease and kidney failure in CKD patients.
DAPA-CKD is an international, multi-center, randomized, double-blind Phase 3 clinical trial involving 4,245 patients to assess the efficacy of Dagley Net Therapy level 2 to 4 (stages 2-4) CKD patients, regardless of whether they have type 2 diabetes (T2D).
In March, AstraZenecon announced that Dagrid's treatment of CKD patients was significant, with patients benefiting clinically earlier than expected, as recommended by the Independent Data Monitoring Board (DMC), so the phase 3 trial could end prematurely.
details of the trial will be presented at future medical conferences.
: . . . FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for The Treatment of Patients With Chronic Kidney Disease. Retrieved July 28, 2020, from.